These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8621264)

  • 1. Optimal regimes for local IL-2 tumour therapy.
    Den Otter W; De Groot JW; Bernsen MR; Heintz AP; Maas R; Hordijk GJ; Hill FW; Klein WR; Ruitenberg EJ; Rutten VP
    Int J Cancer; 1996 May; 66(3):400-3. PubMed ID: 8621264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local low-dose IL-2 therapy.
    Den Otter W; Balemans L; Battermann JJ; Bernsen MR; Cadee JA; Dobrowolski Z; Everse LA; Fiszer-Maliszewska L; Gavhumende R; De Groot JW; De Groot K; Hennink WE; Hill FW; Jurgenliemp-Schulz I; Klein WR; Koten JW; Maas RA; Steerenberg P; Stewart R; Zembala M
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1280-6. PubMed ID: 10429975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming of the antitumor response promotes efficacy of interleukin-2 therapy.
    Everse LA; Bernsen MR; Dullens HF; Den Otter W
    Cancer Immunol Immunother; 1997 Jun; 44(4):221-9. PubMed ID: 9222281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.
    Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
    Eur J Cancer; 2004 Jun; 40(9):1412-7. PubMed ID: 15177501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength.
    Fiszer-Maliszewska L; Den Otter W; Mordarski M
    Cancer Immunol Immunother; 1999 Feb; 47(6):307-14. PubMed ID: 10203060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
    Pappo I; Lotem M; Klein M; Orda R
    Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.
    Bernsen MR; Dullens HF; Den Otter W; Heintz PM
    J Interferon Cytokine Res; 1995 Jul; 15(7):641-5. PubMed ID: 7553236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunotherapy with local low doses of interleukin-2.
    Den Otter W; Maas RA; Koten JW; Dullens HF; Bernsen M; Klein WR; Rutten VP; Steerenberg PA; Balemans L; Ruitenberg EJ
    In Vivo; 1991; 5(6):561-5. PubMed ID: 1810439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
    J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.
    Perez-Soler R; Khokhar AR; Lopez-Berestein G
    Cancer Res; 1987 Dec; 47(24 Pt 1):6462-6. PubMed ID: 3315188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
    Maas RA; Dullens HF; De Jong WH; Den Otter W
    Cancer Res; 1989 Dec; 49(24 Pt 1):7037-40. PubMed ID: 2582444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-inducibility is diminished in tumour-bearing mice.
    Hung PL; Stöger I; Karczag E; Minárovics J; Földes I
    Acta Microbiol Hung; 1989; 36(4):433-8. PubMed ID: 2484273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
    Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Uchida S; Fujioka K; Takada Y; Onoda T; Orita K
    Cancer Res; 1990 Nov; 50(21):7003-7. PubMed ID: 2208166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.
    Maas RA; Van Weering DH; Dullens HF; Den Otter W
    Cancer Immunol Immunother; 1991; 33(6):389-94. PubMed ID: 1908746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.